Antibody production

Area of Science:

• Biotechnology
• Biopharmaceutical Manufacturing
• Cell Culture Technology

Background:

• The widespread clinical and commercial success of monoclonal antibodies necessitates large-scale production.
• This has driven significant global expansion in manufacturing capacity, including larger bioreactors (up to 20,000 L).
• There is a continuous effort to enhance process efficiency and reduce manufacturing costs.

Purpose of the Study:

• To review current technologies for monoclonal antibody production, focusing on mammalian cell culture.
• To discuss advancements in upstream processing, including expression technology and fed-batch cultures.
• To explore future trends in monoclonal antibody manufacturing, particularly in accelerating process development and cell line creation.

Main Methods:

• Review of existing literature and industry practices in mammalian cell culture for monoclonal antibody production.
• Analysis of improvements in expression technology and process optimization strategies.
• Discussion of cell line development timelines and potential future innovations.

Main Results:

• Upstream processing productivity has improved 100-fold over the last 15 years.
• Improvements stem from enhanced expression systems and optimized fed-batch culture techniques.
• Cell line creation remains a critical bottleneck in reducing overall process development time.

Conclusions:

• Mammalian cell culture is a cornerstone of modern monoclonal antibody manufacturing.
• Significant progress has been made in upstream productivity, but cell line development requires further acceleration.
• Future efforts will likely focus on streamlining early-stage development to expedite the availability of therapeutic materials.